Ocera Therapeutics Inc news

   Watch this stock
Showing stories 1 - 10 of about 78   

Articles published

OCRX 5.25 -0.07 (-1.32%)
price chart
Ocera Therapeutics to Announce Fourth Quarter and Full Year 2014 Financial ...
PALO ALTO, Calif., March 2, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that it will release its fourth quarter and ...
Ocera Therapeutics Finally Ready To Reward Investors
Furthermore, to bluntly state the obvious, Ocera has had a rough 2014. Investors unfamiliar with the company would probably look at the stock chart and move on to the next assuming that something catastrophic had occurred to warrant such a steep price ...
Ocera Therapeutics to Present at 35th Annual Cowen and Company Health ...
Ocera Therapeutics, Inc. OCRX, -1.67% a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that company management will be presenting at the 35th Annual Cowen and Company Health Care ...
Ocera Therapeutics, Inc. Files SEC Form SC 13G, Statement of Acquisition of ...
By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C. , by NewsRx journalists, a U.S.
Ocera Therapeutics Well-Capitalized After The Merger
Ocera Therapeutics (NASDAQ:OCRX) announced the closing of a merger with Tranzyme on July 15. Immediately following the closing of the merger, certain of the Ocera investors invested approximately $20 million in the company through a private ...
Ocera Therapeutics Promotes Michael Byrnes to Chief Financial Officer
PALO ALTO, Calif., Dec. 3, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical-stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced the appointment of Michael Byrnes as ...
Related articles »  
Ocera Therapeutics (OCRX) Reports OCR-002 Phase 2a Missed Primary Endpoint
Ocera Therapeutics, Inc. (Nasdaq: OCRX) today announced preliminary topline results from a Phase 2a investigator-sponsored study evaluating the company's drug candidate OCR-002 (ornithine phenylacetate) versus placebo in patients with upper ...
Ocera sinks on mixed clinical trial results (OCRX)  Seeking Alpha (registration)
Ocera Announces Preliminary Topline Results From Phase 2a Investigator ...  CNNMoney
Ocera Therapeutics: A Potential Multibagger Biopharmaceutical Company
Ocera Therapeutics [Nasdaq: (NASDAQ:OCRX)] announced the initiation of its phase 2b double blind, controlled, randomized clinical trial in early January 2014.
Related articles »  
Brokerages Anticipate Ocera Therapeutics to Post ($0.38) Earnings Per Share ...
Brokerages have set a 12-month consensus target price of $17.00 for the company and are expecting that the company will post ($0.38) earnings per share for the current quarter, according to Zacks.
Can the Rally in Ocera Therapeutics (OCRX) Shares Continue?
Ocera Therapeutics Inc (OCRX - Snapshot Report) has been on the move lately as the stock has risen by 8.9% in the past four weeks, and it is currently trading well above its 20-Day SMA.